Tags

Type your tag names separated by a space and hit enter

US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness research.
Pharmacoeconomics. 2011 Aug; 29(8):687-92.P

Abstract

BACKGROUND

Section 114 of the 1997 US FDA Modernization Act (FDAMA) is an important vehicle for pharmaceutical companies to promote the economic value of their drugs to formulary decision makers, but little is known about how the Section has been interpreted and used.

METHODS

We conducted a web-based survey of a convenience sample of 35 outcomes directors of major pharmaceutical and biotechnology companies. We asked them about their interpretation of, and experiences with, Section 114, as well as their views regarding the FDA's role in the matter, and whether the advent of comparative effectiveness research (CER) will affect the use of Section 114 promotions.

RESULTS

Of the 35 experts, 16 (46%) completed the survey. 81% stated they always or frequently consider using Section 114 when making promotional claims for drugs. 75% stated that the FDA should issue guidance on how to make such promotions to payers, especially what qualifies as "healthcare economic information" and "competent and reliable scientific evidence." Most expected to use Section 114 to a greater extent in the future, and agreed that the increased focus on CER would increase Section 114 use.

CONCLUSIONS

The survey suggests strong awareness about Section 114 among the outcomes directors and some use of the Section for promotional purposes. It also reflects a belief that CER will increase use of Section 114 promotions, and that guidance from the FDA is needed. More clarity - and, ideally, flexible interpretation - from the FDA is warranted, especially given the rise of CER.

Authors+Show Affiliations

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21732704

Citation

Neumann, Peter J., et al. "US FDA Modernization Act, Section 114: Uses, Opportunities and Implications for Comparative Effectiveness Research." PharmacoEconomics, vol. 29, no. 8, 2011, pp. 687-92.
Neumann PJ, Lin PJ, Hughes TE. US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness research. Pharmacoeconomics. 2011;29(8):687-92.
Neumann, P. J., Lin, P. J., & Hughes, T. E. (2011). US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness research. PharmacoEconomics, 29(8), 687-92. https://doi.org/10.2165/11590510-000000000-00000
Neumann PJ, Lin PJ, Hughes TE. US FDA Modernization Act, Section 114: Uses, Opportunities and Implications for Comparative Effectiveness Research. Pharmacoeconomics. 2011;29(8):687-92. PubMed PMID: 21732704.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - US FDA Modernization Act, section 114: uses, opportunities and implications for comparative effectiveness research. AU - Neumann,Peter J, AU - Lin,Pei-Jung, AU - Hughes,Tom E, PY - 2011/7/8/entrez PY - 2011/7/8/pubmed PY - 2011/10/28/medline SP - 687 EP - 92 JF - PharmacoEconomics JO - Pharmacoeconomics VL - 29 IS - 8 N2 - BACKGROUND: Section 114 of the 1997 US FDA Modernization Act (FDAMA) is an important vehicle for pharmaceutical companies to promote the economic value of their drugs to formulary decision makers, but little is known about how the Section has been interpreted and used. METHODS: We conducted a web-based survey of a convenience sample of 35 outcomes directors of major pharmaceutical and biotechnology companies. We asked them about their interpretation of, and experiences with, Section 114, as well as their views regarding the FDA's role in the matter, and whether the advent of comparative effectiveness research (CER) will affect the use of Section 114 promotions. RESULTS: Of the 35 experts, 16 (46%) completed the survey. 81% stated they always or frequently consider using Section 114 when making promotional claims for drugs. 75% stated that the FDA should issue guidance on how to make such promotions to payers, especially what qualifies as "healthcare economic information" and "competent and reliable scientific evidence." Most expected to use Section 114 to a greater extent in the future, and agreed that the increased focus on CER would increase Section 114 use. CONCLUSIONS: The survey suggests strong awareness about Section 114 among the outcomes directors and some use of the Section for promotional purposes. It also reflects a belief that CER will increase use of Section 114 promotions, and that guidance from the FDA is needed. More clarity - and, ideally, flexible interpretation - from the FDA is warranted, especially given the rise of CER. SN - 1179-2027 UR - https://www.unboundmedicine.com/medline/citation/21732704/US_FDA_Modernization_Act_section_114:_uses_opportunities_and_implications_for_comparative_effectiveness_research_ L2 - https://dx.doi.org/10.2165/11590510-000000000-00000 DB - PRIME DP - Unbound Medicine ER -